Comparison of “Huaxi-1” or “histidine-tryptophan-ketoglutarate” cardioplegia in an animal model
Authors:
Open Access
- 5 June 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1385253
Abstract
Background: Using a pig model of cardiopulmonary bypass, we compared outcomes after cardioplegia either with our in-house “Huaxi-1” solution containing natural blood and crystalloid or with the entirely crystalloid, commercially available “histidine-tryptophan-ketoglutarate” solution.Methods: Cardiopulmonary bypass was established in 13 healthy male pigs. Twelve of those animals were randomized to receive a single dose of either Huaxi-1 or entirely crystalloid cardioplegia, while the remaining animal was assigned to receive Huaxi-1 without randomization. All animals were then subjected to whole-heart ischemia for 90 min, followed by 2 h of reperfusion, after which myocardial injury was assessed in terms of cardiac function, myocardial pathology and levels of biomarkers in plasma, while levels of high-energy phosphate in myocardium were assayed using liquid chromatography.Results: Animals given Huaxi-1 cardioplegia required significantly less time to be weaned off bypass, they received significantly lower doses of norepinephrine, and they showed significantly higher levels (mean ± SD) of adenosine triphosphate (14 ± 4 vs. 8 ± 2 µg/mg, P = 0.005), adenosine diphosphate (16 ± 2 vs. 13 ± 2 µg/mg, P = 0.046), and total adenine nucleotide (37 ± 4 vs. 30 ± 3 µg/mg, P = 0.006) in myocardium after 2 h of reperfusion. They also showed less severe bleeding, edema and injury to mitochondria and myofibers in myocardium. The two groups did not differ significantly in doses of inotropic drugs received, cardiac output or levels of biomarkers in plasma.Conclusions: In this animal model of healthy hearts subjected to 90 min of ischemia, Huaxi-1 cardioplegia may be superior to entirely crystalloid cardioplegia for promoting energy generation and attenuating ischemia/reperfusion injury in myocardium.Keywords
This publication has 33 references indexed in Scilit:
- Non-responsiveness to cardioprotection by ischaemic preconditioning in Ossabaw minipigs with genetic predisposition to, but without the phenotype of the metabolic syndromeBasic Research in Cardiology, 2022
- IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST ActionBasic Research in Cardiology, 2021
- Scavenging right atrial Bretschneider histidine-tryptophan-ketoglutarate cardioplegia: Impact on hyponatremia and seizures in pediatric cardiac surgery patientsThe Journal of Thoracic and Cardiovascular Surgery, 2020
- Single-dose cardioplegia protects myocardium as well as traditional repetitive dosing: A noninferiority randomized studyThe Journal of Thoracic and Cardiovascular Surgery, 2020
- Mitochondria and Reactive Oxygen Species. Which Role in Physiology and Pathology?2011
- La cardioplégie sanguine : Avantages et inconvénientsAnnales Françaises d'Anesthésie et de Réanimation, 2011
- One single dose of histidine–tryptophan–ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: A prospective randomized studyThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Multidose Cold Oxygenated Blood Is Superior to a Single Dose of Bretschneider HTK-Cardioplegia in the PigThe Annals of Thoracic Surgery, 2009
- Quantitative effects of myocardial edema on the left ventricular pressure-volume relationThe Journal of Thoracic and Cardiovascular Surgery, 1993
- Ultrastructural and cytochemical correlates of myocardial protection by cardiac hypothermia in manThe Journal of Thoracic and Cardiovascular Surgery, 1980